ArticleJournal of the Pediatric Infectious Diseases Society2020
Implementation of a Pragmatic Biomarker-Driven Algorithm to Guide Antibiotic Use in the Pediatric Intensive Care Unit: the Optimizing Antibiotic Strategies in Sepsis (OASIS) II Study.
Article in Journal of the Pediatric Infectious Diseases Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Artificial intelligence in intensive care units: a scoping review addressing the translational gap to clinical practice.Korean journal of anesthesiology · 2026Article
- Role of biomarkers in pediatric sepsis: What evidence says?World journal of clinical pediatrics · 2026Review
- Biomarker-guided antibiotic stewardship in neonatology: time for implementation?Pediatric research · 2025Article
- Use of procalcitonin in therapeutic decisions in the pediatric intensive care unit.Annals of intensive care · 2025Review
- Biomarkers for Serious Bacterial Infections in Febrile Children.Biomolecules · 2024Review
- Antimicrobial stewardship using electronic prescribing systems in hospital settings: a scoping review of interventions and outcome measures.JAC-antimicrobial resistance · 2022Article
- Procalcitonin in Pediatric Sepsis: What Is It Good for?Journal of the Pediatric Infectious Diseases Society · 2021Article
- CON: Procalcitonin does not have clinical utility in children with community-acquired pneumonia.JAC-antimicrobial resistance · 2021Article
- Prospective Observational Study to Determine Kinetics of Procalcitonin in Hospitalized Children Receiving Antibiotic Therapy for Non-Critical Acute Bacterial Infections.Infectious diseases and therapy · 2021Article
- Challenges of Antibiotic Stewardship in the Pediatric and Neonatal Intensive Care Units.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- Real-World Application of a Procalcitonin Monitoring Protocol in a Pediatric Intensive Care Unit.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- Utility of Procalcitonin as a Biomarker for Sepsis in Children.Journal of clinical microbiology · 2020Review
Corrections and comments
- Erratum issuedCorrigendum.2019
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBiomarkers can facilitate safe antibiotic discontinuation in critically ill patients without bacterial infection.
methodsWe tested the ability of a biomarker-based algorithm to reduce excess antibiotic administration in patients with systemic inflammatory response syndrome (SIRS) without bacterial infections (uninfected) in our pediatric intensive care unit (PICU). The algorithm suggested that PICU clinicians stop antibiotics if (1) C-reactive protein <4 mg/dL and procalcitonin <1 ng/mL at SIRS onset and (2) no evidence of bacterial infection by exam/testing by 48 hours. We evaluated excess broad-spectrum antibiotic use, defined as administration on days 3-9 after SIRS onset in uninfected children. Incidence rate ratios (IRRs) compared unadjusted excess length of therapy (LOT) in the 34 months before (Period 1) and 12 months after (Period 2) implementation of this algorithm, stratified by biomarker values. Segmented linear regression evaluated excess LOT among all uninfected episodes over time and between the periods.
resultsWe identified 457 eligible SIRS episodes without bacterial infection, 333 in Period 1 and 124 in Period 2. When both biomarkers were below the algorithm's cut-points (n = 48 Period 1, n = 31 Period 2), unadjusted excess LOT was lower in Period 2 (IRR, 0.53; 95% confidence interval, 0.30-0.93). Among all 457 uninfected episodes, there were no significant differences in LOT (coefficient 0.9, P = .99) between the periods on segmented regression.
conclusionsImplementation of a biomarker-based algorithm did not decrease overall antibiotic exposure among all uninfected patients in our PICU, although exposures were reduced in the subset of SIRS episodes where biomarkers were low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.